Literature DB >> 33572349

Melanotic Neuroectodermal Tumor of Infancy (MNTI) and Pineal Anlage Tumor (PAT) Harbor A Medulloblastoma Signature by DNA Methylation Profiling.

Oscar Lopez-Nunez1, Rita Alaggio2, Ivy John3, Andrea Ciolfi4, Lucia Pedace5, Angela Mastronuzzi5, Francesca Gianno6, Felice Giangaspero6,7, Sabrina Rossi2, Vittoria Donofrio8, Giuseppe Cinalli8, Lea F Surrey9, Marco Tartaglia4, Franco Locatelli5,10, Evelina Miele5.   

Abstract

MNTI is a rare tumor of indeterminate histogenesis and molecular signature. We performed methylation and copy number variation (CNV) profiles in patients with MNTI (n = 7) and PAT (n = 1) compared to the methylation brain tumor classifier v11b4 (BT-C) and the medulloblastoma (MB) classifier group 3/4 v1.0 (MB3/4-C). The patients' mean age was 8 months (range: 4-48). The BT-C classified five MNTIs and one PAT (relapse) as class family MB-G3/G4, subclass group 3 (score: >0.9). The remaining two MNTIs and PAT (primary) were classified as class family plexus tumor, subclass pediatric (scores: >0.45). The MB3/4-C classified all MNTIs as high-risk MB-G3, Subtype II (score: >0.45). The primary PAT was classified as subtype III (score: 0.99) and its relapse as subtype II/III. MNTI and PAT clustered close to MB-G3. CNV analysis showed multiple rearrangements in one PAT and two MNTIs. The median follow-up was 54 months (four MNTIs in remission, one PAT died). In conclusion, we demonstrated that MNTI shares a homogenous methylation profile with MB-G3, and possibly with PAT. The role of a multipotent progenitor cell (i.e., early cranial neural crest cell) in their histogenesis and the influence of the anatomical site, tumor microenvironment, and other cytogenetic events in their divergent biologic behavior deserve further investigation.

Entities:  

Keywords:  DNA methylation; copy number variation; medulloblastoma; melanotic neuroectodermal tumor; melanotic progonoma; pineal anlage tumor

Year:  2021        PMID: 33572349      PMCID: PMC7916108          DOI: 10.3390/cancers13040706

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  85 in total

1.  Uncoupling of bait-protein expression from the prey protein environment adds versatility for cell and tissue interaction proteomics and reveals a complex of CARP-1 and the PKA Cbeta1 subunit.

Authors:  Andrea Erlbruch; Chien-Wen Hung; Joerg Seidler; Katrin Borrmann; Frank Gesellchen; Norbert König; Dieter Kübler; Friedrich W Herberg; Wolf D Lehmann; Dirk Bossemeyer
Journal:  Proteomics       Date:  2010-08       Impact factor: 3.984

Review 2.  Melanotic neuroectodermal tumor of infancy--a neoplasm of neural crese origin. Report of a case associated with high urinary excretion of vanilmandelic acid.

Authors:  E D Borello; R J Gorlin
Journal:  Cancer       Date:  1966-02       Impact factor: 6.860

3.  A medulloblastoma-like tumour with melanin formation.

Authors:  P V Best
Journal:  J Pathol       Date:  1973-05       Impact factor: 7.996

Review 4.  Medulloblastoma in the age of molecular subgroups: a review.

Authors:  Kyle Juraschka; Michael D Taylor
Journal:  J Neurosurg Pediatr       Date:  2019-10-01       Impact factor: 2.375

5.  BRAFV600E Mutation in Melanotic Neuroectodermal Tumor of Infancy: Toward Personalized Medicine?

Authors:  Carolina C Gomes; Marina G Diniz; Grazielle Helena F de Menezes; Wagner H Castro; Ricardo S Gomez
Journal:  Pediatrics       Date:  2015-07       Impact factor: 7.124

6.  VRK2A is an A-type lamin-dependent nuclear envelope kinase that phosphorylates BAF.

Authors:  Danielle G May; Benjamin V Benson; Dae In Kim; Winnie G Shivega; Manaal H Ali; Randolph S Faustino; Alexandre R Campos; Kyle J Roux
Journal:  Mol Biol Cell       Date:  2017-06-21       Impact factor: 4.138

7.  Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience.

Authors:  David Capper; Damian Stichel; Felix Sahm; David T W Jones; Daniel Schrimpf; Martin Sill; Simone Schmid; Volker Hovestadt; David E Reuss; Christian Koelsche; Annekathrin Reinhardt; Annika K Wefers; Kristin Huang; Philipp Sievers; Azadeh Ebrahimi; Anne Schöler; Daniel Teichmann; Arend Koch; Daniel Hänggi; Andreas Unterberg; Michael Platten; Wolfgang Wick; Olaf Witt; Till Milde; Andrey Korshunov; Stefan M Pfister; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2018-07-02       Impact factor: 17.088

8.  Modeling medulloblastoma in vivo and with human cerebellar organoids.

Authors:  Claudio Ballabio; Marica Anderle; Matteo Gianesello; Chiara Lago; Evelina Miele; Marina Cardano; Giuseppe Aiello; Silvano Piazza; Davide Caron; Francesca Gianno; Andrea Ciolfi; Lucia Pedace; Angela Mastronuzzi; Marco Tartaglia; Franco Locatelli; Elisabetta Ferretti; Felice Giangaspero; Luca Tiberi
Journal:  Nat Commun       Date:  2020-01-29       Impact factor: 14.919

9.  Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development.

Authors:  Xindong Liu; Xin Chen; Bo Zhong; Aibo Wang; Xiaohu Wang; Fuliang Chu; Roza I Nurieva; Xiaowei Yan; Ping Chen; Laurens G van der Flier; Hiroko Nakatsukasa; Sattva S Neelapu; Wanjun Chen; Hans Clevers; Qiang Tian; Hai Qi; Lai Wei; Chen Dong
Journal:  Nature       Date:  2014-01-19       Impact factor: 49.962

View more
  3 in total

Review 1.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Tumours of the Oral Cavity and Mobile Tongue.

Authors:  Susan Muller; Wanninayake M Tilakaratne
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 2.  Malignant Superficial Mesenchymal Tumors in Children.

Authors:  Philippe Drabent; Sylvie Fraitag
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

3.  Melanotic neuroectodermal tumor of infancy in the mandible: A case report.

Authors:  Ryoko Takeuchi; Akinori Funayama; Yohei Oda; Tatsuya Abé; Manabu Yamazaki; Satoshi Maruyama; Takafumi Hayashi; Jun-Ichi Tanuma; Tadaharu Kobayashi
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.